CE separations of glycans taken from the cancer drug, Trastuzumab (Herceptin (R)), were accomplished using phospholipid additives. Glycans were labeled with 1-aminopyrene-3,6,8-trisulfonic acid and were separated with efficiencies as high as 510 000 theoretical plates in a 60.2 cm 25 mu m id fused-silica capillary. The thermally tunable phospholipid was loaded into the capillary when it possessed a viscosity similar to that of water. The temperature was increased, and the separations were performed when the material exhibited higher viscosity. Enzymes were integrated into the separation with the phospholipid additive. Neuraminidase, beta 1-4 galactosidase, and beta-N-acetylglucosaminidase were injected into the capillary without covalent modification and used for enzyme hydrolysis. Exoglycosidase enzymes cleaved the terminal glycan residues. The glycan sequence could be verified based on enzyme specificity. Neuraminidase was used to determine total glycan content of the low-abundance glycans containing sialic acid. beta 1-4 Galactosidase and beta-N-acetylglucosaminidase were used sequentially in-capillary, to determine the structure of the high-abundance glycans.